GlaxoSmithKline received approval for Relenza antiviral treatment for use in the prevention of influenza in 15 European countries. Relenza may be given to adults and children age five and older to prevent flu. The drug, which is inhaled, was also approved for treating flu in children age 5 and older. Relenza was previously approved in Europe for the treatment of flu in adults and children age 12 and older. Relenza received FDA approval for the prevention of influenza in adults and children 5...